Source - RNS
RNS Number : 5268L
AstraZeneca PLC
03 October 2016
 

3 October 2016 15:00

 

 

Transparency Directive

Voting Rights and Capital

 

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. On 30 September 2016 the issued share capital of AstraZeneca PLC with voting rights is 1,265,021,933 ordinary shares of US$0.25.  No shares are held in Treasury.  Therefore, the total number of voting rights in AstraZeneca PLC is 1,265,021,933.

 

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

 

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com    

 

CONTACTS

 

Media Enquiries

 

 

 

 

 

Neil Burrows

 

UK/Global

 

+44 203 749 5637

 

Vanessa Rhodes

 

UK/Global

 

+44 203 749 5736

 

Karen Birmingham

 

UK/Global

 

+44 203 749 5634

 

Rob Skelding

 

UK/Global

 

+44 203 749 5821

 

Jacob Lund

 

Sweden

 

+46 8 553 260 20

 

Michele Meixell

 

US

 

+1 302 885 2677

 

Investor Relations



UK



Thomas Kudsk Larsen

 

 

 

+44 203 749 5712

 

Craig Marks

 

Finance, Fixed Income, M&A

 

+44 7881 615 764

 

Nick Stone

 

Respiratory & Autoimmunity

 

+44 203 749 5716

 

Henry Wheeler

 

Oncology

 

+44 203 749 5797

 

Christer Gruvris

Infection & Neuroscience

+44 203 749 5711

US



Lindsey Trickett

 

Cardiovascular & Metabolic Diseases

 

+1 240 543 7970

 

Mitchell Chan

 

 Oncology

 

+1 240 477 3771

 

Toll-free


+1 866 381 7277

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

-ENDS-

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRLLFEFIDLVIIR

Related Charts

AstraZeneca (AZN)

+164.25p (+3.99%)
delayed 18:15PM